Sinobioway's CTLA-4 monoclonal antibody approved for market launch, becoming China's first domestically approved anti-CTLA-4 monoclonal antibody.

On December 25th, the official website of the National Medical Products Administration announced that Xinda Biotech's Ipilimumab N01 injection has been approved for marketing. It is approved for use in combination with PD-1 monoclonal antibody for neoadjuvant therapy in patients with stage IIB-III microsatellite high instability or mismatch repair deficient colon cancer that is surgically resectable. It is reported that this drug is the first domestically produced anti-CTLA-4 monoclonal antibody approved in China, and also the first anti-CTLA-4 monoclonal antibody approved for neoadjuvant therapy in colon cancer globally.